GEN Exclusives

More »

GEN News Highlights

More »
Aug 26, 2013

BARDA Awards Novan $7.8M to Develop Thermal Burns Treatment

  • Novan Therapeutics has inked a deal with the U.S. Department of Health and Human Services to advance the development of a nitric oxide-based therapy as a topical treatment for thermal burns. The Biomedical Advanced Research and Development Authority (BARDA) awarded this contract and will provide funding of $7.8 million over two years.

    According to the company, the project is designed to enable the future clinical investigation of the medical countermeasure and will support development of the Nitric Oxide Advanced Healing, or NOAH, technology including formulation work, nonclinical toxicology, and proof of concept studies in models of deep partial thickness and full thickness thermal injuries.

    “The challenge is to create stable nitric oxide drugs that 'perform on command' and deliver a controlled, sustained dose that will supplement the body's ability to regenerate tissue,” said Nathan Stasko, president of Novan. “Our platform technology has allowed us to pursue the development of drugs intended to harness the healing power of nitric oxide with results extending far beyond bioterrorism.”

    Novan's existing efforts include developing nitric oxide therapies for combat casualties, multidrug resistant infections, and chronic wounds. The company has evaluated the effects of topical nitric oxide therapies in several porcine wound models. Additionally, in May, Novan Therapeutics presented results from a Phase 1 trial demonstrating that nitric oxide releasing drug candidate SB204 reduced colonization of the acne causing bacteria Propionibacterium acnes.

Add a comment

  • You must be signed in to perform this action.
    Click here to Login or Register for free.
    You will be taken back to your selected item after Login/Registration.

Related content


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Easing Restrictions for Terminal Patients

Should the Federal Government Pass a “Right to Try” Bill Allowing Terminally Ill Patients Access to Experimental Medicines?

More »